FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 381 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Mohs Surgery for Skin Cancer: What to Know and What to... March 28, 2023 Oncolytic Virus Enables the Immune System to Attack Tumors October 12, 2023 Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially... July 12, 2021 Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... August 5, 2022 Load more HOT NEWS EMA Recommends Extension of Indications for Durvalumab in the Management of... Could A Diabetes Diagnosis Help Detect Pancreatic Cancer Early? Cancer in My Community: Obstacles to Caring for People With Cancer... FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and...
